Group 1 - The company Pang Donglai has announced the recruitment of all released prisoners, with 2% of the 1000 positions at the new store allocated for them [2] - ByteDance's Douyin Group VP responded to rumors about a potential Hong Kong listing, cautioning investors about misleading information regarding "Byte concept stocks" [3] - Over 20 million new employment form workers in China are now covered by occupational injury insurance, with specific policies for delivery workers and ride-hailing drivers [4] Group 2 - Prosus's OLX Group has agreed to acquire the French automotive classifieds platform La Centrale for €1.1 billion, with the deal expected to close by the end of the year [5] - Xiaomi's Lei Jun stated that the company will invest at least 50 billion yuan in chip development over the next decade [6] - Yushutech's CEO announced the upcoming release of a 1.8-meter humanoid robot, highlighting a significant growth rate of 50% to 100% in the domestic robotics industry [7] Group 3 - The Trump administration plans to require chip manufacturers to match domestic production with imports, imposing tariffs on companies that fail to maintain a 1:1 ratio [8] - Times Angel is actively responding to a renewed investigation request from competitor Align Technology, expressing confidence in a favorable outcome [9] - Starbucks announced a $1 billion restructuring plan, which includes closing underperforming stores, notably the first Reserve Roastery in Seattle [9] Group 4 - Chinese scientists achieved nearly 100% utilization of precious metal atoms in catalytic reactions, paving the way for more efficient and sustainable catalysts [10] - Reports indicate a warming relationship between Trump and Musk, as they collaborate on making AI models available to federal agencies at competitive prices [11] - Trump approved a deal allowing TikTok to continue operating in the U.S., establishing a joint venture where U.S. investors will hold a majority stake [12][13]

Core Viewpoint - The company, Times Angel, expresses confidence in its ability to respond to a recent investigation initiated by competitor Align Technology, asserting that the claims are baseless [1] Group 1 - On September 24, Times Angel announced that Align Technology filed a new investigation request with the U.S. International Trade Commission (ITC) [1] - The complaint by Align Technology alleges violations related to the import and sale of certain clear aligners and their components under Section 337 of the Tariff Act of 1930 [1] - Times Angel emphasizes its commitment to actively respond to the investigation and believes it will achieve a favorable outcome [1]

ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 (Incorporated in Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code: 6699) （股份代號：6699） NOTIFICATION LETTER 通知信函 September 23, 2025 Dear Non-Registered Holder of securities of Angelalign Technology Inc. (the "Company") (Note 1) Notification of publication of Corporate Communication on the Company's website We hereby notify you that the following corporate communication (the "Current Corporate Communication") of the Company in both English and Chinese, is ...

（於開曼群島註冊成立的有限公司） 股份代號 : 6699 中期報告 2025 INTERIM REPORT 中期報告 目錄 02 公司資料 03 業績概要 05 管理層討論與分析 18 非國際財務報告準則計量 20 企業管治及其他資料 39 中期財務資料的審閱報告 40 中期簡明綜合全面收益表 41 中期簡明綜合財務狀況表 43 中期簡明綜合權益變動表 45 中期簡明綜合現金流量表 46 簡明綜合財務資料附註 90 釋義 2025年中期報告 02 公司資料 董事會 執行董事 胡杰章先生 （首席執行官） 黃琨先生 宋鑫先生 董莉女士 非執行董事 馮岱先生 （主席） 獨立非執行董事 韓小京先生 石子先生 周浩先生 審核委員會 周浩先生 （主席） 韓小京先生 石子先生 薪酬委員會 韓小京先生 （主席） 胡杰章先生 黃琨先生 石子先生 周浩先生 提名委員會 馮岱先生 （主席） 董莉女士 （自2025年6月24日起獲委任為 提名委員會成員） 韓小京先生 石子先生 周浩先生 宋鑫先生 （自2025年6月24日起不再擔任 提名委員會成員） 公司秘書 李亮賢先生 （自2025年5月15日起獲委任） 朱凌波先生 （自2025年 ...

Core Viewpoint - The report from 兴证国际 highlights the strong performance and strategic initiatives of 时代天使 (06699) in the first half of 2025, emphasizing its ability to adapt to market conditions and maintain its leading position through various measures such as price adjustments and market expansion [1] Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of $161 million, representing a year-on-year growth of 33.1%, with a gross margin of 62.4% and an adjusted net profit of approximately $20 million, up 84.8% year-on-year [2] - The global market outside of China contributed approximately $72 million in revenue, a significant increase of 123.4% year-on-year, accounting for 44.4% of total revenue [2] - The domestic market generated $90 million in revenue, showing a modest growth of 0.7% year-on-year, while operating profit reached approximately $17 million, up 52.1% year-on-year, with an operating profit margin of 19.2%, an increase of 6.5 percentage points [2] Group 2: Market Expansion and Strategy - The total number of cases reached 225,800 in the first half of 2025, reflecting a year-on-year increase of 47.7%, with 117,200 cases outside of mainland China, a growth of 103.5% [3] - In mainland China, the company achieved approximately 108,600 cases, a 14.0% increase year-on-year, driven by strategic price adjustments and a focus on early treatment and lower-tier markets [3] - The revenue growth in the domestic market lagged behind the case growth due to a decline in average selling prices [3] Group 3: Globalization and Service Enhancement - The company is expanding its market presence outside of mainland China by leveraging high-quality medical design support and stable delivery, along with continuous education and training led by key opinion leaders [4] - Plans are in place to establish or expand manufacturing and design facilities in key global locations, such as Brazil and Southeast Asia, to support operations in the U.S. [4] - Significant resources are being allocated to upgrade data security facilities and operational processes to comply with data security and privacy regulations in all major countries and regions where the company operates [4]

Core Viewpoint - The report from Xingzheng International recommends focusing on Times Angel (06699), highlighting its significant growth in case numbers and strong performance in global expansion during the first half of 2025 [1] Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of $161 million, a year-on-year increase of 33.1%, with a gross margin of 62.4% and an adjusted net profit of approximately $20 million, up 84.8% year-on-year [2] - Revenue from global markets outside of China reached approximately $72 million, a year-on-year increase of 123.4%, accounting for 44.4% of total revenue [2] - Revenue from the Chinese market was $90 million, a year-on-year increase of 0.7%, making up 55.6% of total revenue, with operating profit of approximately $17 million, up 52.1% year-on-year [2] Group 2: Case Growth - The total number of cases reached 225,800, a year-on-year increase of 47.7%, with 117,200 cases outside of mainland China, up 103.5% year-on-year, representing 51.9% of total cases [3] - In mainland China, the company achieved approximately 108,600 cases, a year-on-year increase of 14.0%, driven by strategic price adjustments in response to competition [3] - The slower revenue growth in the domestic market compared to case growth is attributed to a decline in average selling prices [3] Group 3: Global Expansion - The company is enhancing its global presence by leveraging high-quality medical design support and stable delivery, along with continuous education training led by key opinion leaders [4] - Plans are in place to establish or expand manufacturing and design facilities in key global locations, such as Brazil and Southeast Asia, to support the U.S. market [4] - Significant resources are being invested to upgrade data security facilities and operational processes to comply with data security and privacy regulations in all major countries and regions where the business operates [4]

Core Viewpoint - Guosheng Securities maintains a "Buy" rating for Times Angel (06699), citing rapid growth in overseas markets and projecting revenue and net profit growth from 2025 to 2027 [1] Financial Projections - Expected revenues for Times Angel are $331 million, $393 million, and $469 million for 2025, 2026, and 2027, representing year-on-year growth of 23.2%, 18.8%, and 19.3% respectively [1] - Projected net profits are $13 million, $22 million, and $34 million for the same years, with year-on-year growth of 4.5%, 74.5%, and 53.9% respectively [1] Recent Performance - In the first half of 2025, Times Angel achieved revenue of $161 million, a year-on-year increase of 33.1% [1] - The net profit for the same period was $14.2 million, reflecting a significant year-on-year growth of 583.6% [1] - Adjusted net profit reached $19.5 million, marking an 84.8% year-on-year increase [1] Market Dynamics - The company is experiencing steady growth in the domestic market while showing strong performance in overseas markets, with the number of overseas cases exceeding expectations [1] - Ongoing localization efforts and overseas capacity expansion are expected to enhance global service capabilities [1] - The introduction of multiple innovative products and solutions continues to improve the product portfolio [1] Strategic Investments - The strategic investment in Shuyaki, acquiring a 35% stake, aims to deepen the company's presence in emerging markets and increase the penetration rate of invisible orthodontics [1]

Core Viewpoint - Guosheng Securities maintains a "buy" rating for Times Angel (06699), citing rapid growth in overseas markets and projecting significant revenue and profit increases from 2025 to 2027 [1] Financial Projections - Expected revenues for Times Angel are projected to be $331 million, $393 million, and $469 million for 2025, 2026, and 2027, respectively, representing year-on-year growth of 23.2%, 18.8%, and 19.3% [1] - Projected net profits for the same years are $13 million, $22 million, and $34 million, with year-on-year growth rates of 4.5%, 74.5%, and 53.9% [1] Recent Performance - For the first half of 2025, Times Angel reported revenues of $161 million, a year-on-year increase of 33.1% [1] - The net profit for the same period was $14.2 million, reflecting a substantial year-on-year growth of 583.6% [1] - Adjusted net profit for 2025H1 was $19.5 million, showing an 84.8% increase year-on-year [1] Market Dynamics - The company is experiencing steady growth in the domestic market while showing impressive performance in overseas markets, with the number of overseas cases exceeding expectations [1] - Ongoing localization efforts and expansion of overseas production capacity are expected to enhance global service capabilities [1] - The introduction of multiple innovative products and solutions continues to improve the company's product portfolio [1] Strategic Investments - Times Angel has made a strategic investment in Shuyaki, acquiring a 35% stake, which is expected to deepen its presence in emerging markets and increase the penetration rate of invisible orthodontics [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 時代天使科技有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06699 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | 本月底法定/註冊股本總額： ...

Core Viewpoint - The company reported strong financial performance for H1 2025, with significant growth in both revenue and net profit, driven by international expansion and improved domestic operations [1][2]. Financial Performance - The company achieved revenue of $161 million in H1 2025, representing a 33% increase year-over-year [1]. - Net profit attributable to shareholders reached $15 million, up 363% compared to the previous year [1]. - The number of cases handled was 225,800, reflecting a 47.7% increase [1]. International Expansion - The company saw a substantial increase in overseas cases, totaling 117,200, which is a 103.5% increase, and now accounts for 51.9% of total cases [1]. - Overseas revenue reached $72 million, marking a 123% increase, with its share of total revenue rising to 44% [1]. - The gross margin for the company was 61.2%, an increase of 2.96 percentage points, while the net profit margin for the overseas segment improved significantly, narrowing losses by 44.5 percentage points [1]. Domestic Operations - Domestic cases increased to 109,000, a 14% rise, with revenue of $90 million, a slight increase of 0.7% [1]. - The net profit from domestic operations was $17 million, up 52%, with a net profit margin of 19.2%, an increase of 6.5 percentage points [1][2]. Cost Management - The improvement in domestic net profit margin was attributed to the increased allocation of fixed costs from overseas operations and effective cost control measures [2]. - The overall gross margin for H1 2025 was 62.4%, remaining stable year-over-year, with a net profit margin of 9.1%, up 6.5 percentage points [2]. - The sales expense ratio, management expense ratio, and R&D expense ratio were 33.3%, 13.8%, and 7.9%, respectively, showing year-over-year decreases of 6.4, 4.5, and 0.7 percentage points [2]. Future Outlook - The company slightly adjusted its profit forecasts for 2025-2027, predicting net profits of $8.6 million, $15 million, and $27.8 million, respectively [2]. - The company is positioned as a leading player in the invisible orthodontics market, with strong brand and product capabilities, focusing on grassroots market penetration domestically and accelerating breakthroughs in overseas markets [2].